Stockscreener 앱 받기
108.08
1.10%
-1.20
전일 마감가:
$109.28
열려 있는:
$108.97
하루 거래량:
704.04K
Relative Volume:
1.32
시가총액:
$3.12B
수익:
$267.23M
순이익/손실:
$-83.50M
주가수익비율:
-34.75
EPS:
-3.11
순현금흐름:
$-59.99M
1주 성능:
-20.17%
1개월 성능:
-23.74%
6개월 성능:
+34.31%
1년 성능:
+58.34%
1일 변동 폭
$106.71
$113.23
1주일 범위
$103.01
$133.00
52주 변동 폭
$55.17
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
명칭
Genedx Holdings Corp
전화
888-729-1206
주소
333 LUDLOW STREET, STAMFORD
WGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
108.08 | 3.16B | 267.23M | -83.50M | -59.99M | -3.11 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Canaccord Genuity | Buy |
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2025-05-15 | 개시 | Guggenheim | Buy |
| 2025-05-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-07-10 | 개시 | Craig Hallum | Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
모두보기
Genedx Holdings Corp 주식(WGS)의 최신 뉴스
GeneDx (NASDAQ:WGS) Shares Up 7.9%Should You Buy? - MarketBeat
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
What makes GeneDx Holdings Corp stock attractive todayJuly 2025 Sentiment & Technical Pattern Based Buy Signals - baoquankhu1.vn
MACD Signal: Is GeneDx Holdings Corp stock forming a triangle patternQuarterly Market Summary & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum - Seeking Alpha
GeneDx stock drops again: WGS slides on 2026 outlook as JPM talk nears - TechStock²
GeneDx (NASDAQ:WGS) Trading Down 8.9%Time to Sell? - MarketBeat
CEO Change: Can GeneDx Holdings Corp Equity Warrant continue delivering strong returnsRate Cut & Long Hold Capital Preservation Tips - baoquankhu1.vn
RSI Check: Is GeneDx Holdings Corp. Equity Warrant stock positioned well for digital economyJuly 2025 Pullbacks & High Conviction Investment Ideas - Bộ Nội Vụ
Cathie Wood Sells Meta and Illumina, Loads Up on Early-Stage Genomics Stocks - Blockonomi
Cathie Wood Dumps Meta, Loads Up on Beaten-Down GeneDx Stock - CoinCentral
GeneDx expects 2026 revenue between $540-555 million amid growth By Investing.com - Investing.com Nigeria
Aug Update: What are the risks of holding GeneDx Holdings CorpNew Guidance & Capital Protection Trading Alerts - baoquankhu1.vn
Market Pulse: What is the Moat Score of GeneDx Holdings Corp2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
GeneDx Reports Strong 2025 Results and 2026 Growth Outlook - TipRanks
GeneDx (NASDAQ:WGS) Shares Gap DownHere's Why - MarketBeat
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next - TechStock²
GeneDx stock falls after 2026 guidance disappoints investors By Investing.com - Investing.com Canada
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance - BioSpace
GeneDx Partners With Komodo Health to Advance Rare Disease Research - Yahoo Finance
Genedx shares down 2.5% after announcing preliminary Q4 results, 2026 outlook - marketscreener.com
GeneDx expects 2026 revenue between $540-555 million amid growth - Investing.com
GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know - MSN
Peregrine Capital Management LLC Has $8 Million Stock Holdings in GeneDx Holdings Corp. $WGS - MarketBeat
Why GeneDx Holdings Corp. stock could rally in 2025Swing Trade & Smart Money Movement Tracker - Улправда
Why GeneDx Holdings Corp. Equity Warrant stock is rated strong buyJuly 2025 Review & Stepwise Trade Signal Guides - Улправда
How GeneDx Holdings Corp. stock trades during market volatilityMarket Activity Summary & Reliable Price Breakout Signals - Улправда
Is GeneDx Holdings Corp. Equity Warrant stock positioned for digital transformation2025 Trading Volume Trends & Advanced Swing Trade Entry Plans - Улправда
GeneDx partners with Komodo Health to create comprehensive rare disease dataset - Investing.com Canada
GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset - Business Wire
Is GeneDx Holdings (WGS) Pricing Look Attractive After Mixed Long Term Share Performance - Yahoo Finance
Published on: 2026-01-13 07:12:59 - ulpravda.ru
GeneDx Announces GenomeDx Prenatal, Expanding Genomic Diagnosis into Prenatal Care - marketscreener.com
GeneDx to launch whole genome sequencing test for fetal anomalies By Investing.com - Investing.com Canada
New prenatal genome test offers faster answers after troubling ultrasounds - Stock Titan
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care - Business Wire
A Look At GeneDx Holdings (WGS) Valuation After New CMO Appointment And Record Rare Disease Genomics Year - Yahoo Finance
GeneDx appoints Dr. Linda Genen as CMO - MSN
GeneDx Holdings Corp.Class A Common Stock (NQ: WGS - FinancialContent
GeneDx appoints Linda Genen as chief medical officer By Investing.com - Investing.com Australia
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care - marketscreener.com
Should GeneDx’s GUARDIAN Newborn Genomics Accolade Reshape the Investment Narrative for WGS Investors? - simplywall.st
Genomic newborn screening may find serious diseases traditional tests miss - Stock Titan
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025 - Business Wire
(WGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2024 Earnings Call Transcript - MSN
What Do Analysts Think About GeneDx Holdings Corp. (WGS)? - Insider Monkey
Simplify Asset Management Inc. Sells 41,071 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference - marketscreener.com
Ajooni Biotech Limited Uptrend in Early Stages Indicators Say YesVolatility Index Analysis & You’ve Never Seen Stock Picks Like These - earlytimes.in
GeneDx Holdings Corp. $WGS Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Genedx Holdings Corp (WGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Genedx Holdings Corp 주식 (WGS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 16 '25 |
Sale |
143.87 |
3,855 |
554,616 |
8,731 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 16 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
25,094 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 16 '25 |
Sale |
143.89 |
10,857 |
1,562,185 |
14,237 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 09 '25 |
Option Exercise |
0.00 |
2,462 |
0 |
6,655 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 09 '25 |
Sale |
159.28 |
1,266 |
201,648 |
5,389 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 09 '25 |
Option Exercise |
0.00 |
6,547 |
0 |
9,983 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Dec 09 '25 |
Sale |
159.28 |
3,639 |
579,620 |
6,344 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 01 '25 |
Option Exercise |
0.00 |
717 |
0 |
4,570 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Dec 01 '25 |
Sale |
162.54 |
377 |
61,276 |
4,193 |
| RUCH JOSHUA | Director |
Nov 24 '25 |
Sale |
160.37 |
38,000 |
6,093,967 |
11,941 |
2.51%
0.74%
자본화:
|
볼륨(24시간):